Novelix Pharma. (536565)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue growth of 813.21% and profit growth of 566.67% show strong recent momentum, albeit from a tiny base.
• Reported ROE of 20.34% is high, and the Piotroski F-Score of 7/9 suggests improving reported fundamentals.
• Latest quarter's ₹48 Cr revenue shows meaningful revenue scale relative to the ₹16 Cr market cap, though profit conversion is only ₹1 Cr.
• PEG of 0.10 indicates apparent cheapness if the very high growth rate can be sustained.

Concerns

• Net margin is thin: ₹1 Cr profit on ₹48 Cr sales (~2%), and a P/E of 66.24 leaves little room for error.
• ROCE of 0.96% versus ROE of 20.34% is inconsistent and suggests hidden leverage, unusual items, or capital structure distortions.
• Current price ₹19.88 is below the stated 52-week range of ₹38-70; promoter holding is N/A, creating data and governance uncertainty.
• No dividend and a 0% yield; a ₹16 Cr microcap carries significant liquidity and speculative risk.

AI Analysis

At ₹19.88, this healthcare research, analytics and technology microcap has a ₹16 crore market cap, so my first rule applies: size alone makes it speculative, not investable. The headline growth is extraordinary—sales up 813.21% and profits up 566.67%—but I have learned to distrust percentages when the base is microscopic. The latest quarter shows ₹48 crore in sales and only ₹1 crore net profit; that is a thin margin. A P/E of 66.24 means I am paying 66 years of current earnings for this tiny profit pool. The PEG of 0.10 looks tempting, but it is built on 567% profit growth; such a ratio is only as good as that growth. P/B of 4.10 against book value of ₹4.85 is not cheap for a company whose ROCE is just 0.96%. How can ROE be 20.34% while ROCE is under 1%? That gap tells me either there is hidden leverage, or the reported numbers have not yet revealed the true operating economics. A 7/9 Piotroski score is encouraging, but it measures one-year accounting quality, not durable competitive advantage. The stated 52-week range of ₹38 to ₹70 does not include today's price of ₹19.88—that is impossible; it tells me the tape is broken or the business has fallen sharply. I cannot rely on multiples built on inconsistent data. Promoter holding is not disclosed, there is no dividend, and the yield is 0%. Graham would call this a speculation with explosive growth numbers needing verification. If the company can sustain sales, improve margins, and demonstrate genuine ROCE, it might become interesting. Until then, I will watch from the sidelines. Price is what you pay; value is what you get. Here, I cannot get a clear read on value.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer